Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Alexey K. Shaytan

dblp:09/7927 · DBLP profile ↗
← Back
2ranked-venue papers
0as first author
2since 2021 · last 2026
—ORCID · none

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 2 · 2 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 75% Medical and health informatics · 25%

Topics — the 4 heaviest of 5, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Medical and health informatics
drug development
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025
Bioinformatics and computational biology › drug discovery
drug repositioning
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025
Bioinformatics and computational biology › drug discovery
drug response prediction
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025
Bioinformatics and computational biology › molecular informatics
molecular design
0.912025
AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025

Methods — techniques the papers use, named apart from their topics

artificial intelligence · 0.9
YearPublicationVenuePosition
2026 DSCA-HLAII: A dual-stream cross-attention model for predicting peptide-HLA class II interaction and presentation
abstract
MOTIVATION: The interaction between peptides and human leukocyte antigen class II (HLA-II) molecules plays a pivotal role in adaptive immune responses, as HLA-II mediates the recognition of exogenous antigens and initiates T cell activation through peptide presentation. Accurate prediction of peptide-HLA-II binding serves as a cornerstone for deciphering cellular immune responses, and is essential for guiding the optimization of antibody therapeutics. Researchers have developed several computational approaches to identify peptide-HLA-II interaction and presentation. However, most computational approaches exhibit inconsistent predictive performance, poor generalization ability and limited biological interpretability. RESULTS: In this study, we present DSCA-HLAII, a novel predictive framework for peptide-HLA-II interactions and presentation based on a dual-stream cross-attention architecture. The framework proposes a dual-stream cross-attention (DSCA) mechanism to integrate pre-trained semantic embedding ESMC with sequence-level ONE-HOT features. The DSCA mechanism effectively models the interaction dynamics between peptides and HLA-II molecules, enabling the precise identification of key binding sites. Experimental results demonstrate that DSCA-HLAII consistently surpasses existing state-of-the-art approaches, demonstrating high accuracy and robustness in predicting peptide-HLA-II interactions and presentation. We further demonstrate the capability of DSCA-HLAII for predicting peptide binding cores and assessing antibody immunogenicity, which is expected to advance artificial intelligence-based peptide drug discovery.
Shutao Chen, Alexey K. Shaytan, Youyu Wang
PLoS Comput. Biol.4
2025 AI in drug development: advances in response, combination therapy, repositioning, and molecular design
Ren Qi, Shujia Liu, Xingqi Hui, Alexey K. Shaytan
Sci. China Inf. Sci.4